glp 1 coverage 2025 GLP-1 drugs are rewriting America's food preferences, says IFF ISPOR 2025: Exploring reasons for

Back Unger, RH, Ketterer, H Dupr, J, Eisentraut, I (1967) 'The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs', Journal Clinical Investigation , 46/4, 63045

GLP-1 receptor agonists (short for glucagon-like peptide 1) are a class of medications that mimic a natural hormone in the body

Injectable Wegovy produced an average weight loss of around 15 percent in major trials, while tirzepatide, sold as Zepbound for obesity, has produced around 20 percent or more weight loss depending on dose and population

A well-designed patient portal is where these interactions happen, and it directly influences outcomes and long-term retention

While I'm excited that patients may soon have more options, enthusiasm should not blind us to the risks